3 Healthcare Stocks Using Technology to Drive Growth
CORAL GABLES, FL / ACCESSWIRE / October 26, 2018 / Big data is not just for normal industries anymore. In fact, there are additional sectors that have just begun to gain investor interest with regard to new advancements in technology. The global big data in the healthcare market is gaining interest and this has been due to the introduction of personalized healthcare systems and demand for high-quality healthcare services. With this technology, healthcare providers are adding to their capabilities by analyzing patient behavior towards a particular treatment and diagnostic patterns, in order to provide them with customized and highly cost-effective services. It should also be noted that things like telemedicine are also growing in popularity. Ease of use, accessibility, and other factors have led to its growth.
With a new wave of interest sparked by these updates for the healthcare industry, we're looking at three stocks that could be pushing the margin on innovation within the space: Premier Health Group, Inc. (PHGRF)(PHGI.CN), MYnd Analytics, Inc. (MYND), and Anavex Life Sciences Corp. (AVXL).
Premier Health Group, Inc. (PHGRF)(PHGI.CN) is focused on expanding through strategic deals with other public health companies. Just this month Premier announced that it has selected Reliq Health Technologies Inc. as its exclusive technology partner. Premier's HealthVue primary care clinics will be provided with a HealthVue-branded telemedicine, remote monitoring & AI solution for its clinical staff and more than 100,000 active patients. Reliq Health Technologies is a healthcare technology company that specializes in developing innovative software solutions for the Community Care market.
HealthVue's telehealth platform can assist users in Prescription Refill, review of lab and test results, mental health counseling, birth control counseling, diet and nutritional counseling, sinus infection, referrals and even general health questions. According to HealthVue, they have already services thousands of patient visits this year along with thousands of bookings made online.
For More Information On Premier Health Group, Click Here
MYnd Analytics, Inc. (MYND) is a predictive analytics company that has developed a decision support tool to help physicians reduce trial and error treatment in mental health and provide more personalized care to patients. The Company's Psychiatric EEG Evaluation Registry, or PEER Online, is a registry and reporting platform that allows medical professionals to exchange treatment outcome data for patients referenced to objective neurophysiology data obtained through a standard electroencephalogram (EEG). Based on the Company's original physician-developed database, there are now more than 40,000 outcomes for over 11,000 unique patients in the PEER registry.
Last month the company announced that it had entered into definitive agreements with George C. Carpenter IV, President and Chief Executive Officer, Robin L. Smith, Chairman, as well as John Pappajohn, and Peter Unanue, each a director of the Company, and entities affiliated with Michal Votruba, a member of the Board of Directors of MYnd Analytics and Director of Life Sciences for the European-based RSJ-Gradus fund, relating to a private placement of an aggregate of 459,458 units for $1.85 per unit, with each unit consisting of one share of Common Stock and one Common Stock Purchase Warrant to purchase one share of Common Stock for $2.00 per share.
For More Information On MYnd Analytics, Click Here
Anavex Life Sciences Corp. (AVXL) is a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer's disease, Rett syndrome andother central nervous system (CNS) diseases. Today the company announced that it has presented new clinical data for ANAVEX®2-73 in a late-breaking oral presentation at the 2018 Clinical Trials on Alzheimer's Disease (CTAD) Meeting.
"These results further confirm the impact of actionable genetic variants that were previously identified through a full, unbiased genomic analysis of ANAVEX®2-73 in Alzheimer's disease, raising optimism for the future of biomarker-guided precision medicine to effectively combat this devastating disease," said Professor Harald Hampel, M.D., Ph.D., M.A., M.Sc., AXA Research Fund & Sorbonne University Excellence Chair, Departments of Neuroscience and Neurology, Sorbonne University, Paris, France. Professor Hampel is the president of the Alzheimer Precision Medicine Initiative (APMI).
Shares of Anavex were up by more than 6% on Friday morning.
For More Information On Anavex, Click Here
What Is Stock Price (StockPrice.com)?
Stock Price is defined as the price of a single share of a number of saleable stocks of a public company. A stock price is the highest amount an investor or trader is willing to pay for the stock, or the lowest amount that it can be bought for.
StockPrice.com was created for everyone that wants the latest stock quotes, stock charts, company news, and the best financial content.
At Stock Price (StockPrice.com), you get free stock quotes, up-to-date news, international market data, social interaction and the best financial content that will help you manage your financial life.
Legal Disclaimer
Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. JSG Communications, LLC which owns www.StockPrice.com is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release.
JSG Communications, LLC, which owns www.StockPrice.com, may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. JSG Communications, LLC, which owns www.StockPrice.com, may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two. Pursuant to an agreement between MIDAM VENTURES, LLC an affiliate of JSG COMMUNICATIONS LLC and Premier Health Group Inc. we were hired for a period from 10/1/2018 - 4/1/2018 to publicly disseminate information about Premier Health Group Inc. including on the Website and other media including Facebook and Twitter. We were paid $100,000 (CASH) for & were paid "500,000" shares of restricted common shares. We own zero shares of Premier Health Group Inc., which we purchased in the open market. Once the (6)Six month restriction is complete on 4/1/2018 we plan to sell the "500,000" shares of Premier Health Group Inc. that we hold currently in restricted form during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. We may buy or sell additional shares of Premier Health Group Inc. in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. Please click here for full disclaimer.
Contact Information:
SOURCE: StockPrice.com
